CSM
NVO

CAMG Solamere Management’s Novo Nordisk NVO Stock Holding History

CAMG Solamere Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,520
Closed -$218K – 103
2019
Q2 		$218K Sell
8,520
-1,124
-12% -$27.8K 0.1% 89
2019
Q1 		$253K Sell
9,644
-750
-7% -$18.4K 0.13% 89
2018
Q4 		$241K Sell
10,394
-5,236
-33% -$116K 0.13% 90
2018
Q3 		$369K Sell
15,630
-15,556
-50% -$380K 0.19% 80
2018
Q2 		$722K Sell
31,186
-32,656
-51% -$776K 0.36% 66
2018
Q1 		$1.57M Sell
63,842
-2,868
-4% -$75.3K 0.71% 47
2017
Q4 		$1.83M Sell
66,710
-648
-1% -$16.5K 0.81% 47
2017
Q3 		$1.62M Sell
67,358
-150
-0.2% -$3.39K 0.81% 47
2017
Q2 		$1.44M Buy
67,508
+1,214
+2% +$24.5K 0.82% 44
2017
Q1 		$1.14M Sell
66,294
-830
-1% -$14.5K 0.67% 52
2016
Q4 		$1.21M Buy
+67,124
New +$1.22M 0.85% 38

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

CAMG Solamere Management's NVO Position: Q3 2019 in Review

CAMG Solamere Management sold out of Novo Nordisk (NVO) in Q3 2019, closing a stake of 8,520 shares — an estimated $218K sold.

CAMG Solamere Management first reported a position in NVO in Q4 2016 and held it in 11 quarters. The position peaked at $1.83M in Q4 2017. 564 funds tracked by Wall St. Rank hold NVO as of Q3 2019.

  • CAMG Solamere Management reported no remaining Novo Nordisk position as of Q3 2019 after selling out during the quarter.
  • CAMG Solamere Management sold 8,520 Novo Nordisk shares in Q3 2019, an estimated $218K.
  • CAMG Solamere Management first reported a position in Novo Nordisk in Q4 2016 and held it in 11 quarters.
  • CAMG Solamere Management's Novo Nordisk position peaked at $1.83M in Q4 2017.
  • 564 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2019.

Based on CAMG Solamere Management's 13F filing for Q3 2019, filed 14 Nov 2019.